再生元制药公司 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended June 30, 2026OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from __________ to __________ Commission File Number: 000-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) 13-3444607 New York (State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707(Address of principal executive offices, including zip code)(914) 847-7000(Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading SymbolName of each exchange on which registeredCommon Stock - par value $.001 per shareREGNNASDAQ Global Select Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days. Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files). Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growthcompany" in Rule 12b-2 of the Exchange Act. Large acceleratedfiler☒Acceleratedfiler☐Non-accelerated filer☐Smaller reportingcompany☐Emerging growthcompany☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ The number of shares outstanding of each of the registrant's classes of common stock as of July23, 2026: REGENERON PHARMACEUTICALS, INC.QUARTERLY REPORT ON FORM 10-QTABLE OF CONTENTS Page NumbersPART IFINANCIAL INFORMATIONItem 1.Financial Statements (unaudited)2Condensed Consolidated Balance Sheets2Condensed Consolidated Statements of Operations and Comprehensive Income3Condensed Consolidated Statements of Stockholders' Equity4Condensed Consolidated Statements of Cash Flows6Notes to Condensed Consolidated Financial Statements7Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations22Item 3.Quantitative and Qualitative Disclosures About Market Risk43Item 4.Controls and Procedures43PART IIOTHER INFORMATIONItem 1.Legal Proceedings44Item 1A.Risk Factors44Item 2.Unregistered Sales of Equity Securities and Use of Proceeds81Item 5.Other Information81Item 6.Exhibits81SIGNATURE PAGE82 "Altibodies," "ARCALYST ," "Evkeeza ," "EYLEA ," "EYLEA HD ," "Inmazeb ," "Libtayo ," "Lynozyfic ," "Ordspono,""Otarmeni," "Praluent " (in the United States), "REGEN-COV ," "Regeneron ," "Regeneron Genetics Center ," "RGC ," "STEM-Fueled," "Veloci-Bi," "VelociGene," "VelociHum," "VelociMab," "VelocImmune," "VelociMouse," "VelociSuite," "VelociT,""Veopoz ," and "ZALTRAP " are trademarks of Regeneron Pharmaceuticals, Inc. Trademarks and trade names of other companiesappearing in this report are, to the knowledge of Regeneron Pharmaceuticals, Inc., the property of their respective owners. This reportrefers to products of Regeneron Pharmaceuticals, Inc., its collaborators, and other parties. Consult the product label in each territoryfor specific information about such products.™®®®®®®®™™®®®®®™®®®®®®®®®® REGENERON PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)(In millions, except per share data) REGENERON PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)(In millions) Table of Contents REGENERON PHARMACEUTICALS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) 1. Interim Financial Statements Basis of Presentation The interim Condensed Consolidated Financial Statements of Regeneron Pharmaceuticals, Inc. and its subsidiaries ("Regeneron,""Company," "we," "us," and "our") have been prepared in accordance with the instructions to Form 10-Q and Article 10 of RegulationS-X. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company's financial position,results of operations, and cash flows in conformity with acc